An interventional study of Normobaric oxygen therapy and Normobaric oxygen therapy in Colorectal Cancer (CRC), sponsored by 4th Military Clinical Hospital with Polyclinic, Poland. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by 4th Military Clinical Hospital with Polyclinic, Poland · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Colorectal Neoplasms with a site in Poland — 20 open to participants now, 34 under way, 14 of them phase 3. Colorectal Neoplasms · Poland.
Among the 118 studies in Colorectal Neoplasms with a site in Poland, this one is the 68th largest by planned enrollment of the 103 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 with no phase, reaches primary completion later than 17 of the 33 other live ones, and was the 109th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →20 of the 118 studies in Colorectal Neoplasms with a site in Poland are open now. Recruiting first, the newest first:
Takeda · Sites in Poland
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in Poland, United States, Argentina and 16 more countries
Ages 18+
Incyte Corporation · Sites in Poland, United States, Argentina and 19 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Poland, United States, Argentina and 22 more countries
Ages 18+
Pfizer · Sites in Poland, United States, Argentina and 17 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 32 · Phase 3 41
First in 1993; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 254 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 473 across the 103 interventional studies, 143 across the 13 observational. Of the 74 that completed or were terminated, 43 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 118 have an industry lead sponsor. The 10 most frequent:
4th Military Clinical Hospital with Polyclinic, Poland is the lead sponsor of 10 studies on the registry; 8 are open to participants now.
4th Military Clinical Hospital with Polyclinic, Poland has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Colorectal Neoplasms with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT05759923Molecure S.A.First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours | 2027-03-31 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
Add all 10 to your calendar (.ics) → With an account.
Among the 118 studies in Colorectal Neoplasms with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Colorectal cancer (CRC) patients undergoing chemotherapy often experience anemia, oxidative stress, and immune suppression, significantly impacting their quality of life and treatment outcomes. Normobaric oxygen (NBO) therapy, which delivers oxygen at atmospheric pressure with elevated oxygen concentration, has shown a potential to enhance erythropoiesis, reduce oxidative stress, and modulate immune function. However, its efficacy in CRC patients remains underexplored. This study aims to evaluate the effects of NBO exposures on (1) supporting erythropoiesis by measuring erythropoietin (EPO) levels and hypoxia-inducible factors (HIF-1α), (2) reducing oxidative stress and improving stress and emotional well-being, and (3) modulating immune function by assessing cytokine profiles. Secondary objectives include assessing the impact of NBO on patient-reported outcome measures (PROMs) such as stress, anxiety, depression, and quality of life. This is a prospective, randomized, double-blind, placebo-controlled clinical trial. A total of 254 CRC patients undergoing chemotherapy will be randomized 1:1 to receive either active NBO therapy (n=127) or placebo NBO therapy (n=127). The intervention consists of 10 NBO sessions over five weeks. Primary outcomes include biomarkers of erythropoiesis, oxidative stress, and immune response. Secondary outcomes assess quality of life and psychological well-being. Data will be collected at baseline, mid-intervention, post-intervention, and during two follow-up visits (3- and 6-months post-intervention). The study hypothesizes that NBO therapy will improve erythropoiesis, reduce oxidative stress, and enhance immune function in CRC patients, leading to improved quality of life and clinical outcomes. Findings from this trial may establish NBO as a novel supportive therapy for CRC patients undergoing chemotherapy.
The intervention will involve NBO as a supportive treatment for CRC patients undergoing chemotherapy. The NBO protocol consists of regular sessions in a normobaric chamber where patients are exposed to controlled oxygen levels aimed at reducing ox-idative stress, supporting erythropoiesis, and modulating immune function. Patients in the CRC group will undergo 10 NBO sessions across five weeks, with two sessions weekly.
Patient's exposure to NBO conditions in group 1 (aNBO) including: oxygen levels of 32-40% (compared to about 21% in the atmosphere), pressure maintained at 1,500 hPa (about 1,000 hPa outside), carbon dioxide levels between 0.7-1.9% (compared to 0.03% in the atmosphere, and hydrogen levels between 0.5-1% (which is 10 to 20 thousand times higher than in the atmosphere). Exposure time in the NBO chamber will be the standard 2 hours with an additional 20 minutes for preparation and adaptation and 10 minutes for the finalization and decompression period.
Patients' exposure to atmospheric conditions in the same NBO chamber (without normobaric conditions to provide sham-placebo intervention) in group 2 (pNBO): oxygen levels about 21%, pressure maintained at about 1,000 hPa, carbon dioxide levels about o 0.03%, and hydrogen levels about 0.00005% (0.5 parts per million, like in the atmos-phere). The primary comparator in this study is the placebo NBO group (CRC patients; n=127) for CRC patients, which serves to differentiate the specific effects of active NBO from the natural course of treatment without enhanced oxygen exposure.
The patient assessment scheme contains six visits from V0 to V5 with subsequent analytical packages with detailed explanation in 2.8. section. The patient assessment schedule consists of six visits, from V0 to V5, each including specific evaluations and interventions. The study begins with V0 (prequalification/screening), where patient consent is obtained, medical history is collected, and baseline data are recorded. V1 (randomization and pre-test visit) involves the initial assessments, including anemia, stress, immune, genetic markers, and patient-reported outcomes (PROMs). Following this, the first phase of the NBO intervention (sessions 1-5) takes place over five weeks. At V2 (midpoint evaluation), the same set of assessments is repeated to track progress, followed by the second phase of the NBO intervention (sessions 6-10) conducted over the next five weeks. V3 (finalization and post-test visit) marks the completion of the intervention, with a final round of primary and secondary outcome assessments. The study then proceeds with two follow-up visits: V4 (3-months post-NBO) and V5 (6-months post-NBO), where anemia, stress, immune, genetic markers, and PROMs are reassessed to evaluate the long-term effects of the intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient's exposure to NBO conditions in group 1 (aNBO)
Device: Normobaric oxygen therapy
Patients' exposure to atmospheric conditions in the same NBO chamber without normobaric conditions in group 2 (pNBO)
Device: Normobaric oxygen therapy
Patient's exposure to NBO conditions in group 1 (aNBO) including: oxygen levels of 32-40% (compared to about 21% in the atmosphere), pressure maintained at 1,500 hPa (about 1,000 hPa outside), carbon dioxide levels between 0.7-1.9% (compared to 0.03% in the atmosphere, and hydrogen levels between 0.5-1% (which is 10 to 20 thousand times higher than in the atmosphere). Exposure time in the NBO chamber will be the standard 2 hours with an additional 20 minutes for preparation and adaptation and 10 minutes for finalization and the decompression period.
Patients' exposure to atmospheric conditions in the same NBO chamber (without normobaric conditions to provide placebo intervention as the study comparator) in group 2 (pNBO): oxygen levels about 21%, pressure maintained at about 1,000 hPa, carbon dioxide levels about o 0.03%, and hydrogen levels about 0.00005% (0.5 parts per million, like in the atmos-phere).
Erythropoietin (EPO) concentration
Erythropoietin (EPO) concentration \[mU/mL\] will be measured using a quantitative immunoassay (ELISA) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Hypoxia-inducible factor-1α (HIF-1α)
Hypoxia-inducible factor-1α (HIF-1α) \[ng/mL\] will be measured using a quantitative immunoassay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Reticulocyte count
Reticulocyte count \[% of total red blood cells\] will be measured using an automated hematology analyzer at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Red blood cell (RBC)
Red blood cell (RBC) count \[10¹² cells/L\] will be measured using 5-part differential blood morphology on an automated hematology analyzer at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Hemoglobin concentration (HGB)
Hemoglobin concentration (HGB) \[g/dL\] will be measured using an automated hematology analyzer at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Hematocrit
Hematocrit \[%\] will be measured using an automated hematology analyzer at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Serum creatinine
Serum creatinine \[µmol/L\] will be measured using an enzymatic assay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Estimated glomerular filtration rate (eGFR)
Estimated glomerular filtration rate (eGFR) \[mL/min/1.73 m²\] will be calculated using the CKD-EPI equation at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Alanine aminotransferase (ALT)
Alanine aminotransferase (ALT) \[IU/L\] will be measured using an enzymatic assay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Aspartate aminotransferase (AST)
Aspartate aminotransferase (AST) \[IU/L\] will be measured using an enzymatic assay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Fasting glucose
Fasting glucose \[mmol/L\] will be measured using a hexokinase assay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Fasting insulin
Fasting insulin \[µU/mL\] will be measured using an immunoassay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Lipid profile
Lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) \[mmol/L\] will be measured using enzymatic/colorimetric assays at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Iron metabolism (serum iron, total iron-binding capacity [TIBC]
Iron metabolism (serum iron, total iron-binding capacity \[TIBC\] \[µmol/L\], ferritin \[ng/mL\], vitamin B₁₂ \[pg/mL\]) will be measured using immunoassays at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Serum albumin
Serum albumin \[g/L\] will be measured using a bromcresol green assay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
C-reactive protein (CRP)
C-reactive protein (CRP) \[mg/L\] will be measured using a high-sensitivity immunoturbidimetric assay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Reactive oxygen species (ROS) level
Reactive oxygen species (ROS) level \[relative fluorescence units\] will be measured using a chemiluminescence assay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up]
Serum cortisol
Serum cortisol \[µg/dL\] will be measured using a high-sensitivity immunoassay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Gamma-aminobutyric acid (GABA)
Gamma-aminobutyric acid (GABA) \[µmol/L\] will be measured using an enzyme-linked immunosorbent assay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Dopamine
Dopamine \[ng/mL\] will be measured using a competitive immunoassay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Serotonin
Serotonin \[ng/mL\] will be measured using a competitive immunoassay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Fibrinogen
Fibrinogen \[g/L\] will be measured using the Clauss clotting assay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Glycated hemoglobin (HbA₁c)
Glycated hemoglobin (HbA₁c) \[%\] will be measured using high-performance liquid chromatography at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Dehydroepiandrosterone-sulfate (DHEA-S)
Dehydroepiandrosterone-sulfate (DHEA-S) \[µg/dL\] will be measured using an immunoassay at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Systolic blood pressure (SBP)
Systolic blood pressure (SBP) \[mmHg\] will be measured using an automated sphygmomanometer at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Diastolic blood pressure (DBP)
Diastolic blood pressure (DBP) \[mmHg\] will be measured using an automated sphygmomanometer at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Heart rate (HR)
Heart rate (HR) \[beats per minute\] will be measured using an automated sphygmomanometer at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Body mass index (BMI)
Body mass index (BMI) \[kg/m²\] will be calculated from measured weight and height at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Body surface area (BSA)
Body surface area (BSA) \[m²\] will be calculated using the Mosteller formula from measured weight and height at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Waist-to-hip ratio (WHR)
Waist-to-hip ratio (WHR) \[ratio\] will be calculated from measured waist and hip circumferences at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Tumor necrosis factor-α (TNF-α)
Tumor necrosis factor-α (TNF-α) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Interleukin-1β (IL-1β)
Interleukin-1β (IL-1β) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Interleukin-6 (IL-6)
Interleukin-6 (IL-6) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Interleukin-10 (IL-10)
Interleukin-10 (IL-10) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Monocyte chemoattractant protein-1 (MCP-1/CCL2)
Monocyte chemoattractant protein-1 (MCP-1/CCL2) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Macrophage inflammatory protein-1α (MIP-1α/CCL3)
Macrophage inflammatory protein-1α (MIP-1α/CCL3) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Macrophage inflammatory protein-1β (MIP-1β/CCL4)
Macrophage inflammatory protein-1β (MIP-1β/CCL4) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Vascular endothelial growth factor A (VEGF-A)
Vascular endothelial growth factor A (VEGF-A) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Platelet-derived growth factor-BB (PDGF-BB)
Platelet-derived growth factor-BB (PDGF-BB) \[pg/mL\] will be measured using a multiplex immunoassay (Luminex) at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Stress level (self-assessment)
The Perceived Stress Questionnaire (PSQ-30) is a 30-item self-report instrument designed to assess perceived stress over the previous month. Each item is rated on a 4-point Likert scale (1 = "almost never" to 4 = "usually"), yielding a raw score that can range from 30 (minimum) to 120 (maximum). Higher raw scores indicate greater perceived stress (worse outcome). The PSQ-30 will be administered at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Anxiety and depression levels (self-assessment)
The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report questionnaire comprising two subscales: HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D). Each subscale contains 7 items scored on a 4-point Likert scale (0 = "not at all" to 3 = "very often"), yielding subscale scores from 0 (minimum) to 21 (maximum). Higher scores indicate greater symptom severity (worse outcome). The HADS total score (sum of HADS-A and HADS-D) ranges from 0 to 42. The HADS will be administered at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Quality of live level (self-assessment)
EuroQol Five-Dimension Five-Level questionnaire (EQ-5D-5L) index score \[-0.59 to 1.00; higher = better health\] will be derived from five domains-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each rated on a 5-point scale (1 = no problems to 5 = extreme problems). Health states will be converted to a single index value using the Polish EQ-5D-5L value set. The EQ-5D-5L will be administered at V1, V2, V3, V4, and V5.
Time frame: From enrollment to the end of 6th month follow-up
Plan to share: Undecided
Start is estimated for Nov 2025; primary completion for Nov 2027, 24 months later.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 24 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
4th Military Clinical Hospital with Polyclinic, Poland